Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Aortic Interventions News

Embolic Protection for TAVR
EMBLOK Announces Enrollment of 50th Patient in Clinical Trial for Emblok™ Embolic Protection System for use in TAVR Procedures, Appoints Scientific and Strategic Advisory Board
10/08/2024
Medical device company marks trial milestone in the evaluation of its embolic protection device, creates expert advisory board as it navigates growth opportunity Tampa, FL – October 8, 2024 – EMBLOK™ (emblok.com), a privately held medical...
Medical device company marks trial milestone in the evaluation of its embolic protection device, creates expert advisory board as it navigates growth opportunity Tampa, FL – October 8, 2024 – EMBLOK™ (emblok.com), a privately held medical...
Medical device company marks...
10/08/2024
Vascular Disease Management
thoracic endovascular aortic repair
First Commercial Implant of the GORE® TAG® Thoracic Branch Endoprosthesis in Canada
06/28/2024
The first flexible, off-the-shelf single-branch thoracic endoprosthesis for zone 2 treatment. FLAGSTAFF, AZ (June 27, 2024) — W. L. Gore & Associates (Gore) today announced the first commercial use of the GORE® TAG® Thoracic Branch...
The first flexible, off-the-shelf single-branch thoracic endoprosthesis for zone 2 treatment. FLAGSTAFF, AZ (June 27, 2024) — W. L. Gore & Associates (Gore) today announced the first commercial use of the GORE® TAG® Thoracic Branch...
The first flexible,...
06/28/2024
Vascular Disease Management
AAA Endoprosthesis
Now Indicated for AAA Patients With Highly Angulated Necks
05/01/2024

Gore Media Update

Gore Media Update
FLAGSTAFF, Ariz. (April 30, 2024) — W. L. Gore & Associates (Gore) announces FDA approval of an expanded indication for the GORE® EXCLUDER® Conformable AAA Endoprosthesis, now indicated for patients with aortic neck angulation ≤ 90° and a...
FLAGSTAFF, Ariz. (April 30, 2024) — W. L. Gore & Associates (Gore) announces FDA approval of an expanded indication for the GORE® EXCLUDER® Conformable AAA Endoprosthesis, now indicated for patients with aortic neck angulation ≤ 90° and a...
FLAGSTAFF, Ariz. (April 30,...
05/01/2024
Vascular Disease Management

Advertisement

News
First European Implantation of GORE® TAG® Thoracic Branch Endoprosthesis
02/01/2024
MDR CE mark approval signifies the first off-theshelf single-branch thoracic endoprosthesis for patients requiring zone 2 treatment. PUTZBRUNN, GERMANY (February 1, 2024) — W. L. Gore & Associates, Inc. (Gore) today announced the first...
MDR CE mark approval signifies the first off-theshelf single-branch thoracic endoprosthesis for patients requiring zone 2 treatment. PUTZBRUNN, GERMANY (February 1, 2024) — W. L. Gore & Associates, Inc. (Gore) today announced the first...
MDR CE mark approval signifies...
02/01/2024
Vascular Disease Management
News
W. L. Gore & Associates, Inc. Receives U.S. Food & Drug Administration (FDA) Approval For Lower Profile Gore® VIABAHN® VBX Balloon Expandable Endoprosthesis, Now 6 Fr Sheath Compatible
01/31/2024
With improvements to the stent graft delivery system enabling a 1 Fr profile reduction  on the majority of sizes, the device now offers the most 6 Fr compatible configurations among balloon expandable stent grafts. FLAGSTAFF, Ariz....
With improvements to the stent graft delivery system enabling a 1 Fr profile reduction  on the majority of sizes, the device now offers the most 6 Fr compatible configurations among balloon expandable stent grafts. FLAGSTAFF, Ariz....
With improvements to the stent...
01/31/2024
Vascular Disease Management
News
Gore Receives FDA Approval for Breakthrough Endovascular Device in Complex Aortic Aneurysms
01/25/2024
The GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis approval brings the first branched, all-in-one solution for patients with thoracoabdominal aortic aneurysms and high-surgical risk patients with pararenal aortic aneurysms in patients...
The GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis approval brings the first branched, all-in-one solution for patients with thoracoabdominal aortic aneurysms and high-surgical risk patients with pararenal aortic aneurysms in patients...
The GORE® EXCLUDER®...
01/25/2024
Vascular Disease Management

Advertisement

News
Nectero Medical Announces Initiation of Phase II/III Clinical Trial of the Nectero EAST® System for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms
01/18/2024
Trial to randomize 400 subjects at multiple sites, primarily in the U.S., to evaluate safety and efficacy of the investigational Nectero EAST System for treatment of infrarenal AAA, maximum diameter 3.5-5.0cm TEMPE, Ariz., January 18,...
Trial to randomize 400 subjects at multiple sites, primarily in the U.S., to evaluate safety and efficacy of the investigational Nectero EAST System for treatment of infrarenal AAA, maximum diameter 3.5-5.0cm TEMPE, Ariz., January 18,...
Trial to randomize 400 subjects...
01/18/2024
Vascular Disease Management
News
Gore Announces First Patient Implant in the Arise II Pivotal Study of the GORE® Ascending Stent Graft
12/20/2023
CAUTION: Investigational device. Limited by United States law to investigational use. The first patient implant in the ARISE II Pivotal Study evaluation of the GORE® Ascending Stent Graft represents a major milestone in the development of...
CAUTION: Investigational device. Limited by United States law to investigational use. The first patient implant in the ARISE II Pivotal Study evaluation of the GORE® Ascending Stent Graft represents a major milestone in the development of...
CAUTION: Investigational device....
12/20/2023
Vascular Disease Management
News
CIS Is First to Use Evolut FX to Treat Severe Aortic Stenosis
09/07/2022
HOUMA, LA - Cardiovascular Institute of the South (CIS) is the first in Louisiana to use the latest generation of Medtronic's self-expanding transcatheter aortic valve replacement (TAVR) system, the Evolut FX, designed to enhance ease-of-use...
HOUMA, LA - Cardiovascular Institute of the South (CIS) is the first in Louisiana to use the latest generation of Medtronic's self-expanding transcatheter aortic valve replacement (TAVR) system, the Evolut FX, designed to enhance ease-of-use...
HOUMA, LA - Cardiovascular...
09/07/2022
Vascular Disease Management

Advertisement

News
Study Suggests a More Proximal Landing Zone is Preferred for Thoracic Endovascular Aortic Repair (TEVAR) of Acute Type B Aortic Dissections (aTBAD)
01/25/2022
Rosemont, Ill., January 24, 2022 – A review evaluating the results of thoracic endovascular aortic repair (TEVAR) following acute type B aortic dissection (aTBAD) suggests most patients with aTBAD have less than 2 cm of proximal healthy...
Rosemont, Ill., January 24, 2022 – A review evaluating the results of thoracic endovascular aortic repair (TEVAR) following acute type B aortic dissection (aTBAD) suggests most patients with aTBAD have less than 2 cm of proximal healthy...
Rosemont, Ill., January 24, 2022...
01/25/2022
Vascular Disease Management

Advertisement

Advertisement

Stay in the Know

Vascular Disease Management Newsletter

Advertisement

Advertisement

News

First Aid guidelines
AHA/American Red Cross: Updated First Aid Guidelines Enhance Care for Opioid Overdose, Bleeding, Other Emergencies
11/14/2024
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major...
11/14/2024
Cath Lab Digest
Late-Breaking Trials
Final Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/06/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a...
11/06/2024
Vascular Disease Management
Late-Breaking Trials
Third Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/05/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/05/2024
Vascular Disease Management
Late-Breaking Trials
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Late-Breaking Trials
First Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Image-Guided Therapy
Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single-Device to Treat Peripheral Artery Disease
11/04/2024
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first...
11/04/2024
Vascular Disease Management
Pulmonary Embolism
Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism
11/04/2024
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate...
11/04/2024
Vascular Disease Management
Peripheral Arterial Disease
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
11/04/2024
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November...
11/04/2024
Vascular Disease Management
Patient Awareness
Baby Boomers Beware: More Americans Than Ever Before Now at Higher Risk for Common Blood Vessel Diseases
10/31/2024
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in...
10/31/2024
Vascular Disease Management
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use